Hansa Biopharma has entered an exclusive licensing agreement with SERB S.A. for the development and commercialization of IDEFIRIX (imlifidase) across the EU, UK, Switzerland, Norway, Liechtenstein, Iceland, and MENA regions. This deal includes an upfront payment of €110 million and an additional €5 million upon EMA filing acceptance, significantly strengthening Hansa's financial position and supporting its planned US launch pending FDA approval in 2026. IDEFIRIX is a pioneering treatment for highly sensitized kidney transplant patients, conditionally approved in Europe, offering a breakthrough for patients with limited options. SERB's established commercial presence in these regions is expected to enhance IDEFIRIX's market reach and clinical impact.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Gold and silver prices are under pressure ahead of key U.S. retail sales data that could influence Federal Reserve interest rate decisions. Central banks, led by Poland and China, continue to boost gold reserves, adding 41 tonnes in May, supporting l...
